
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is supported by its differentiated DRP platform, which aims to match stenoparib with patients most likely to benefit, improving the probability of success in precision oncology. Its lead asset is showing encouraging Phase 2 evidence in advanced ovarian cancer, with multiple patients exceeding 30 weeks on therapy, two still benefiting beyond 29 months as of March 2026, and median overall survival now exceeding 25 months, while a recurrent SCLC Phase 2 trial began enrolling in February 2026. Financially, the company had $20 million in cash and $22 million in debt in Q1, and the expanding PARP inhibitor market, which generated about $9.0 billion in 2023 and is forecasted to exceed $21.0 billion by 2031, strengthens the long-term opportunity despite development risk.
Bears say
Allarity Therapeutics is exposed to significant balance sheet and liquidity risk, and that financial fragility makes continued funding of its clinical-stage pipeline uncertain. Its outlook is further weakened by the possibility that product candidates may fail to demonstrate safety and efficacy in clinical trials or after FDA or postmarket approval, which would undermine the value of stenoparib and its DRP companion diagnostic. Even if development succeeds, the company still faces regulatory, commercialization, reimbursement, and competitive risks, alongside adverse shifts in patient and physician interest, macroeconomic conditions, biotech investor sentiment, and healthcare priorities.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Allarity Therapeutics (ALLR) Forecast
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares